Fitusiran Is a Drug to Watch in the Hematology Space in 2025
Clarivate named fitusiran (Alnylam Pharmaceuticals, Sanofi) as a drug to watch in the hematology space for 2025. Fitusiran is part of a generation of novel RNA interference therapies and is designed for subcutaneous administration—either monthly or …